300009 Stock Overview
Anhui Anke Biotechnology (Group) Co., Ltd. More details
| Snowflake Score | |
|---|---|
| Valuation | 5/6 |
| Future Growth | 2/6 |
| Past Performance | 3/6 |
| Financial Health | 6/6 |
| Dividends | 6/6 |
Rewards
Risk Analysis
No risks detected for 300009 from our risk checks.
My Notes
Capture your thoughts, links and company narrative
Anhui Anke Biotechnology (Group) Co., Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CN¥8.98 |
| 52 Week High | CN¥11.77 |
| 52 Week Low | CN¥7.41 |
| Beta | 0.59 |
| 1 Month Change | -2.71% |
| 3 Month Change | 18.31% |
| 1 Year Change | -10.91% |
| 3 Year Change | -27.81% |
| 5 Year Change | -6.23% |
| Change since IPO | 188.92% |
Recent News & Updates
Recent updates
Anhui Anke Biotechnology (Group) Co., Ltd.'s (SZSE:300009) Share Price Is Matching Sentiment Around Its Earnings
Sep 25
Anhui Anke Biotechnology (Group) (SZSE:300009) Will Pay A Dividend Of CN¥0.25
May 23Earnings Working Against Anhui Anke Biotechnology (Group) Co., Ltd.'s (SZSE:300009) Share Price
Mar 01Shareholder Returns
| 300009 | CN Biotechs | CN Market | |
|---|---|---|---|
| 7D | -3.4% | -4.9% | -3.5% |
| 1Y | -10.9% | -17.6% | 10.9% |
Return vs Industry: 300009 exceeded the CN Biotechs industry which returned -17.2% over the past year.
Return vs Market: 300009 underperformed the CN Market which returned 11.8% over the past year.
Price Volatility
| 300009 volatility | |
|---|---|
| 300009 Average Weekly Movement | 6.9% |
| Biotechs Industry Average Movement | 8.8% |
| Market Average Movement | 8.7% |
| 10% most volatile stocks in CN Market | 12.8% |
| 10% least volatile stocks in CN Market | 5.7% |
Stable Share Price: 300009 has not had significant price volatility in the past 3 months compared to the CN market.
Volatility Over Time: 300009's weekly volatility (7%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2000 | 2,986 | Jian Ping Yao | www.ankebio.com |
Anhui Anke Biotechnology (Group) Co., Ltd. develops, produces, and markets pharmaceutical products in China and internationally. The company offers human growth hormone for injection under the Ansomone name; and recombinant human interferon alpha 2b lyophilized powder, liquid, and prefilled syringe for injection, as well as recombinant human interferon alpha 2b cream, eye drop, and suppository under the Anterferon name.
Anhui Anke Biotechnology (Group) Co., Ltd. Fundamentals Summary
| 300009 fundamental statistics | |
|---|---|
| Market cap | CN¥15.02b |
| Earnings (TTM) | CN¥782.53m |
| Revenue (TTM) | CN¥2.77b |
19.2x
P/E Ratio5.4x
P/S RatioIs 300009 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 300009 income statement (TTM) | |
|---|---|
| Revenue | CN¥2.77b |
| Cost of Revenue | CN¥618.84m |
| Gross Profit | CN¥2.15b |
| Other Expenses | CN¥1.36b |
| Earnings | CN¥782.53m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 0.47 |
| Gross Margin | 77.62% |
| Net Profit Margin | 28.29% |
| Debt/Equity Ratio | 0.1% |
How did 300009 perform over the long term?
See historical performance and comparisonDividends
2.8%
Current Dividend Yield53%
Payout RatioCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/19 03:43 |
| End of Day Share Price | 2024/12/19 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Anhui Anke Biotechnology (Group) Co., Ltd. is covered by 15 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Shuchang Liu | Changjiang Securities Co. LTD. |
| Pei Hui Tang | Chasing Securities |
| Pei Cheng | China Galaxy Securities Co., Ltd. |